[Rituximab-induced interstitial lung disease].
The introduction of the anti-CD20 antibody rituximab into clinical practice has improved substantially the prognosis of a variety of haematological and autoimmune diseases. The interstitial lung disease is one of most serious and potentially fatal complications of rituximab therapy. This diagnosis should be considered in patients who have received the drug and present with dyspnea, fever and cough without clear evidence of infection. We report a case of rituximab-induced interstitial lung disease.
Sección Neumonología, Hospital Profesor Alejandro Posadas, Haedo, Buenos Aires. mfercasar@intramed.net.ar
Marcelo
M
Fernández Casares
Gisela
G
Espósito
Alejandra
A
González
Jaime
J
Segovia
María de Los Ángeles
Mde L
Galperín
Eduardo
E
Del Valle
D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008224:Lymphoma, Follicular / Q000188:drug therapy; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab
interstitial lung disease; rituximab